UK Markets closed
NIKKEI 225
27,433.40 +50.84 (+0.19%) HANG SENG
22,069.73 -619.17 (-2.73%) CRUDE OIL
77.96 -1.72 (-2.16%) GOLD FUTURES
1,937.90 -7.70 (-0.40%) DOW
33,783.58 -194.50 (-0.57%) BTC-GBP
18,536.46 -826.96 (-4.27%)
Biogen Inc. (BIIB.MX)
Mexico - Mexico Delayed price. Currency in MXN
Add to watchlist
As of 01:47PM CST. Market open.
| Previous close | 5,375.0098 |
| Open | 0.0000 |
| Bid | 0.0000 x 100 |
| Ask | 6,229.8701 x 100 |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 50 |
| Market cap | 0 |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | 0.00 |
| EPS (TTM) | 390.1680 |
| Earnings date | 01 Feb 2023 - 06 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance
Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.
- Motley Fool
Is Biogen Stock a Buy Now?
Moving new medicines to the market can sometimes make biopharmaceutical companies tons of returns. Biogen (NASDAQ: BIIB) just scored a major new drug approval for an Alzheimer's disease therapy, so investors are understandably rushing to evaluate whether to buy the stock. One key factor that could drive Biogen's outperformance in the next few years is the launch of a new neurology medicine.
- Motley Fool
Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?
Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market.
© 2023 Yahoo. All rights reserved.
